Literature DB >> 23919670

Salvage of recurrent hypopharyngeal carcinoma after primary curative treatment.

Ryuji Yasumatsu1, Torahiko Nakashima, Satoshi Toh, Masahiko Taura, Shizuo Komune.   

Abstract

CONCLUSIONS: There was a moderate chance of cure after surgical salvage of recurrent hypopharyngeal squamous cell carcinoma (SCC). However, surgical salvage was only feasible for early recurrent tumor. Close follow-up surveillance to detect early recurrence is essential after primary treatment of patients.
OBJECTIVES: Despite improvements in surgery, radiotherapy, and chemotherapy, hypopharyngeal SCC has one of the worst prognoses among head and neck malignant diseases. To improve the overall survival and cure rates in patients with hypopharyngeal SCC, the management of recurrent disease as well as initial treatment is important. In this study, the efficacy and results of salvage treatment of recurrent hypopharyngeal SCC after primary curative treatment were evaluated.
METHODS: The management outcomes of 49 patients who were treated for recurrent hypopharyngeal SCC between January 2002 and December 2010 at Kyushu University Hospital were reviewed.
RESULTS: The median time for detection of recurrence from the initial curative treatment was 10.3 months (range 2.1-61.1 months). The total salvage rates of recurrence were 45% (local, 85%; locoregional, 100%; regional, 23%; distant, 19%). The 1- and 3-year tumor-free actuarial survival rates of those patients who received salvage surgery followed by chemotherapy and/or radiotherapy were 96% and 79%, respectively. There was no 3-year survivor among the patients who received only chemotherapy and/or radiotherapy.

Entities:  

Mesh:

Year:  2013        PMID: 23919670     DOI: 10.3109/00016489.2013.815365

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  1 in total

1.  To do or not to do: salvage management for hypopharyngeal cancer after chemoradiation therapy.

Authors:  Pei-Hsin Chu; Ngan-Ming Tsang; Li-Ang Lee; Chun-Ta Liao; Tuan-Jen Fang
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-20       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.